David Bostwick

Dr. David G. Bostwick is a distinguished medical professional and entrepreneur whose business acumen has helped him make significant achievements in the fields of advanced cancer research, diagnostic pathology, and therapeutic technologies. He currently serves as the Chief Executive Officer of Triopsy Inc., the Chief Medical Officer and Laboratory Director of Granger Genetics, and the Chief Executive Officer and General Manager of Rampart Health. Dr. Bostwick’s extensive management experience and entrepreneurial vision have established him as a leading figure in the development of novel diagnostic and therapeutic solutions.

Dr. Bostwick‘s journey began with his academic training and early professional roles, where he displayed a remarkable commitment to advancing medical science. He held academic positions at renowned institutions such as Stanford University Medical Center and the University of Chicago Hospitals & Clinics. His tenure at Mayo Clinic and Mayo Medical School further solidified his reputation as a leading pathologist and educator, contributing to various committees and research initiatives.

In 1999, Dr. Bostwick founded Bostwick Laboratories in Richmond, VA, a company that rapidly grew to become a major player in the diagnostic laboratory industry. Under his leadership, Bostwick Laboratories achieved significant milestones, including generating $178 million in revenue and employing over 1,200 individuals across multiple locations in the United States and the United Kingdom. His visionary approach led to the successful sale of the company to a private equity group in 2011. Dr. Bostwick’s return to the company in 2016 facilitated its merger with Poplar Healthcare, further expanding its reach and capabilities.

Dr. Bostwick‘s entrepreneurial spirit continued with the founding of Granger Genetics in 2013. This innovative company focuses on providing novel companion diagnostics for childhood leukemia, demonstrating its commitment to leveraging cutting-edge technology to improve patient outcomes. In 2020, he expanded Granger Genetics by establishing Granger Pharmacy, a sterile hazardous compounding pharmacy that further supports the company’s mission.

In 2018, Dr. Bostwick founded Rampart Health, based in Orlando, FL, a company dedicated to developing advanced immunotherapy treatments for metastatic cancer and solid tumors. His leadership led to the completion of FDA-cleared phase II clinical trials for the first-in-human multiplex combination immunotherapy, marking a significant advancement in cancer treatment.

As the Chief Scientific Officer of Immunsys, Inc., Dr. Bostwick co-founded the company in 2014, focusing on combining immunotherapy for metastatic prostate cancer and solid tumors. His expertise and strategic direction have been instrumental in advancing the company’s research and clinical trials.

Dr. Bostwick‘s contributions extend beyond his entrepreneurial ventures. He has served on numerous national grant review panels, study sections, and committees, including the American Cancer Society’s Prostate Cancer Task Force and the College of American Pathologists’ Cancer Committee. His dedication to advancing cancer research and treatment is evident in his role as the founder and Editor-in-Chief of the Journal of Urologic Pathology.

Throughout his career, Dr. Bostwick has received numerous honors and awards, including America’s Top Doctors and America’s Top Doctors for Cancer by Castle Connolly Guide, the 21st Century Award for Achievement from the International Biographical Centre in Cambridge, England, and the Ernst & Young Entrepreneur of the Year Award in the Healthcare Division.

Dr. David G. Bostwick‘s professional philosophy is rooted in advancing cancer research and treatment through cutting-edge technology and innovative diagnostic solutions. His steadfast dedication to enhancing patient care, coupled with his entrepreneurial expertise, has established him as a leading figure in the medical community, consistently pushing the limits of what is achievable in cancer diagnostics and therapy.